GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (LTS:0RK9) » Definitions » Cyclically Adjusted PB Ratio

Alligator Bioscience AB (LTS:0RK9) Cyclically Adjusted PB Ratio : 0.02 (As of Jun. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB Cyclically Adjusted PB Ratio?

As of today (2025-06-02), Alligator Bioscience AB's current share price is kr4.169. Alligator Bioscience AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr212.89. Alligator Bioscience AB's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for Alligator Bioscience AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0RK9' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.02   Max: 0.03
Current: 0.02

During the past years, Alligator Bioscience AB's highest Cyclically Adjusted PB Ratio was 0.03. The lowest was 0.02. And the median was 0.02.

LTS:0RK9's Cyclically Adjusted PB Ratio is ranked better than
97.62% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs LTS:0RK9: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alligator Bioscience AB's adjusted book value per share data for the three months ended in Mar. 2025 was kr-5.860. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr212.89 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alligator Bioscience AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alligator Bioscience AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Cyclically Adjusted PB Ratio Chart

Alligator Bioscience AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alligator Bioscience AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.04

Competitive Comparison of Alligator Bioscience AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alligator Bioscience AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Cyclically Adjusted PB Ratio falls into.


;
;

Alligator Bioscience AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alligator Bioscience AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.169/212.89
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Alligator Bioscience AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-5.86/132.8245*132.8245
=-5.860

Current CPI (Mar. 2025) = 132.8245.

Alligator Bioscience AB Quarterly Data

Book Value per Share CPI Adj_Book
201412 44.064 100.225 58.397
201509 0.000 100.228 0.000
201512 255.286 100.276 338.150
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 238.491 101.138 313.212
201612 426.346 102.022 555.071
201703 417.439 102.022 543.475
201706 397.934 102.752 514.396
201709 381.714 103.279 490.913
201712 389.632 103.793 498.616
201803 363.125 103.962 463.939
201806 339.404 104.875 429.858
201809 314.489 105.679 395.272
201812 295.277 105.912 370.309
201903 267.366 105.886 335.386
201906 236.325 106.742 294.073
201909 200.637 107.214 248.564
201912 162.987 107.766 200.886
202003 135.984 106.563 169.496
202006 113.859 107.498 140.684
202009 94.417 107.635 116.513
202012 72.663 108.296 89.121
202103 86.162 108.360 105.615
202106 67.000 108.928 81.699
202109 46.591 110.338 56.086
202112 65.569 112.486 77.425
202203 55.403 114.825 64.088
202206 44.884 118.384 50.359
202209 33.044 122.296 35.889
202212 20.685 126.365 21.742
202303 6.162 127.042 6.442
202306 16.520 129.407 16.956
202309 10.524 130.224 10.734
202312 1.523 131.912 1.534
202403 -6.539 132.205 -6.570
202406 -1.061 132.716 -1.062
202409 -8.477 132.304 -8.510
202412 -14.534 132.987 -14.516
202503 -5.860 132.825 -5.860

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alligator Bioscience AB  (LTS:0RK9) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alligator Bioscience AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alligator Bioscience AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheeletorget 1, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines